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Key Points 
 
(i) What is already known about the topic? 
 
• Mother’s preferences and willingness-to-pay (WTP) for human papillomavirus (HPV) 
vaccines are specific to culture and socio-economic status. 
• HPV vaccines have not been integrated into Hong Kong government’s immunisation 
schedule whilst the uptake rates amongst adolescent girls was 2.4% in 2008 and 9.1% 
in 2012. 
 
(ii) What does the paper add to existing knowledge? 
 
• This study provides new data on how HPV vaccine features are viewed and valued by 
mothers, by measuring how much benefit that mothers are perceived for ideal and 
current vaccine technologies. 
 
• Side-effects, protection against cervical cancer, protection duration, and out-of-pocket 
cost determined the decision to receive or not receive the vaccine. 
 
• The demand for HPV vaccines is high as indicated by maximum WTP but WTP for 
current vaccines is relatively lower than current market price, except for those who 
had a monthly household income of >HK$100,000 (US$12,821). 
 
(iii) What insights does the paper provide for informing health care-related decision making? 
 
• These findings would contribute to policy makings for the improvement of HPV 
vaccine uptake and inform the immunization service in Hong Kong. 
 
• Subsidy or co-payment from government should be considered for the unmet demand 
of HPV vaccination. 
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Mother's preferences and willingness to pay for human papillomavirus vaccination for 1 
their daughters: a discrete choice experiment in Hong Kong 2 
 3 
Abstract 4 
 5 
Objective: To determine the preference of mothers in Hong Kong and their willingness-to-pay 6 
(WTP) for human papillomavirus (HPV) vaccination for their daughters.  7 
Method: A discrete choice experiment survey with a two-alternative study design was 8 
developed. Data was collected from pediatric specialist outpatient clinics from 482 mothers with 9 
daughters aged 8-17 years old. Preferences of the four attributes of HPV vaccines (protection 10 
against cervical cancer, protection duration, side-effects, and out-of-pocket costs) were 11 
evaluated.  The marginal and overall WTP were estimated using multinomial logistic regression. 12 
A subgroup analysis was conducted to explore the impact of socio-economic factors on mothers’ 13 
WTP. 14 
Results: Side-effects, protection against cervical cancer, protection duration, and out-of-pocket 15 
cost determined the decision to receive or not receive the vaccine. All attributes had a 16 
statistically significant effect on the preference of and the WTP for the vaccine. Maximum WTP 17 
for ideal vaccines (i.e. 100% protection, lifetime protection duration and 0% side effects) was 18 
HK$8,976 (US$1,129). The estimated WTP for vaccines currently available was HK$1,620 19 
(US$208), lower than current market price. Among those who had a monthly household income 20 
of >HK$100,000 (US$12,821), the WTP for vaccines currently offered were higher than the 21 
market price.  22 
Conclusions: This study provides new data on how features of the HPV vaccine are viewed and 23 
valued by mothers by determining their perception of ideal or improved and current vaccine 24 
technologies. These findings could contribute to future policies on the improvement of HPV 25 
vaccine and be useful for the immunization service in Hong Kong. 26 
Keywords: vaccination; HPV; willingness-to-pay; discrete choice experiment;  27 
  28 
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Manuscript Text 29 
Introduction 30 
 31 
Cervical cancer was the eighth most common cancer among females in Hong Kong in 2014, 32 
accounting for about 3.3% of all new cancer cases in females(1). In the most recent cancer 33 
registry conducted in Hong Kong, there were 472 cases of cervical cancer diagnosed in 2014 34 
with an age-standardised incidence rate of 8.1 per 100,000 in the population. In the past two 35 
decades, burden of the disease is relatively higher compared to other developed countries(2), 36 
although both the incidence and mortality rates of cervical cancer show a decreasing trend(1). 37 
 38 
To further reduce the burden of cervical cancer, a cervical cancer screening program was 39 
organised and launched in 2004(3) and two preventive vaccines were introduced and became 40 
available for females in the community since 2006(4). The two commercially-available vaccines 41 
offer about 70% protection against various strains of the human papillomavirus (HPV)(5), which 42 
causes cervical carcinoma(6). However, HPV vaccines have yet to be integrated into the 43 
government’s immunisation schedule in Hong Kong(7). Instead, people voluntarily can seek the 44 
vaccine in private clinics with the administration rate for adolescent girls being as low as 2.4% 45 
in 2008 and 9.1% in 2012 due to lack of HPV vaccination program currently organised(4, 8). 46 
However, including the HPV vaccination for girls aged from 12 years old and upwards is 47 
considered a cost-effective option compared to only offering cervical cancer screening (9, 10). 48 
 49 
The success of the HPV vaccination program largely depends on the attitude of local 50 
stakeholders towards the risks and benefits of the vaccination (11-13). For the purpose of policy 51 
decision-making and improving health services, it is important to understand the various factors 52 
that may affect consumer’s demand and their decision towards administering the vaccine. 53 
Factors associated with decision-making not only include the results of economic evaluation but 54 
also other considerations such as consumer’s demand and preference. With regards to the HPV 55 
vaccination, mothers, who are highly involved in the decision to vaccinate or not vaccinate their 56 
daughters aged under 18 years old (14, 15), were therefore regarded as the critical consumer of 57 
the HPV vaccination. This study adopted a discrete choice experiment (DCE) to determine 58 
consumer preference of the HPV vaccine attributes and their willingness-to-pay (WTP) for the 59 
vaccine in Hong Kong. Similar studies have been conducted in other countries (16-20), however 60 
given that consumer preference may be subject to cultural differences, the applicability of 61 
research from overseas to the local community may be limited.  The aim of this study is to 62 
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investigate the mothers’ choices and decision-making when contemplating the attributes of the 63 
HPV vaccination, to determine local mothers’ preferences and their WTPs towards the HPV 64 
vaccination.  It is anticipated that this study will provide useful information on immunization 65 
services in Hong Kong to help create local HPV vaccination policies in a more effective and 66 
economically-sustainable way.   67 
 68 
Methods 69 
 70 
A cross-sectional survey was conducted in two local public hospitals where a stratified sampling 71 
approach was adopted to recruit mothers as subjects who match the inclusion criteria in 72 
paediatric specialist outpatient clinics in the Princess Margaret Hospital (PMH), Kowloon, and 73 
Queen Mary Hospital (QMH), Hong Kong Island. Mother with at least one daughter aged 8-17 74 
years who has not received any HPV vaccination fulfilled the inclusion criteria of the study. 75 
 76 
Target population 77 
 78 
Given that the decision to vaccinate girls aged 8-17 would largely be determined by their 79 
mothers(14, 15), mothers in the paediatric clinics are regarded as the consumers in this study, as 80 
was the case in similar studies conducted overseas(16, 19). As such, fathers or any other carers 81 
of the girls were not considered in this survey. 82 
 83 
Study Design 84 
 85 
Attributes and levels identification 86 
The relevant attributes and levels for DCE have been identified through literature review with 87 
reference to attributes used in the HPV vaccine DCE studies conducted in the US, Canada, the 88 
Netherlands and Vietnam (16-19) and interviews with relevant local experts, consisting of two 89 
paediatricians and two non-paediatric medical practitioners, who are involved in policy-making 90 
and are clinical experts in the fields of vaccinations and infectious diseases. A pilot of these 91 
attributes was conducted in October 2012 when our research team interviewed eight 92 
paediatricians and eight mothers who matched the inclusion criteria to identify the most 93 
important attributes to be included in the DCE survey. As a result, this pilot data shortlisted four 94 
most important attributes: ‘Protection against cervical cancer’, ‘Protection duration’, ‘Side 95 
effects’ and ‘out-of-pocket cost’. Each attribute was assigned by four levels to give the 96 
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participants a range of the best and worst levels in our experimental design. All levels of each 97 
shortlisted attribute were selected based on the overseas DCE studies (16-18). Therefore, the 98 
identification of the four attributes and their relevant levels were justified and supported by 99 
literature review, and expert and respondent input from pilot data. The ‘Protection against 100 
cervical cancer’ levels were expressed in percentages (50% / 70% / 80% / 100%) and presented 101 
in terms of an absolute risk reduction that was mainly used for the description of risk 102 
information in the DCE survey(21). The ‘Protection duration’ levels were expressed in years (2 / 103 
5 / 10 / lifetime = 100 years). The ‘Side effects’ levels concern the potential side-effects 104 
following administration of the HPV vaccination and were expressed in frequency (2:100 / 105 
6:100 / 10:100 / 14:100). The ‘Out-of-pocket cost’ levels were expressed in HK dollars ($0 / 106 
$1,000 / $2,000 / $3,000).  107 
 108 
Discrete choice experimental design 109 
To avoid impractically-large sample sizes, the complete set of combinations of all attribute 110 
levels corresponding to a full factorial design (4*4*4*4=256 hypothetical vaccine profiles) was 111 
not used in this experiment. Rather, an orthogonal design (ORTHOPLAN procedure, IBM SPSS 112 
Statistics for Windows, Version 22.0) was used to produce 16 hypothetical vaccine profiles (see 113 
Table 1) allowing the main effects to be estimated.  114 
 115 
In our experimental design we used choice sets which contained three options: two vaccine 116 
profiles and one “opt-out” option (i.e. no vaccination) (see Table 1 and 2). The “opt-out” option 117 
is a realistic alternative for mothers who choose to vaccinate their daughters or not. Hence, when 118 
including the “opt-out” option, respondents were not forced to choose one of the vaccine 119 
profiles.  120 
 121 
To ensure sufficient statistical efficiency by simultaneously considering respondent fatigue and 122 
cognitive feasibility, each respondent was asked to treat nine choice sets with the first choice set 123 
used for checking the respondents' rationality and the following eight choice sets for the 124 
statistical analyses.(22, 23). All respondents received the same nine choice sets (see Table 2). In 125 
the first choice set, the second vaccine was better than the first vaccine with regard to protection, 126 
protection duration and side effects and the second vaccine cost less than the first one (see Table 127 
2). Respondents who preferred the first to the second vaccine were considered as irrational and 128 
excluded from the analyses. All eight choice sets were established from achieving four desirable 129 
properties(24) of orthogonality (i.e. the independence between attributes), a balanced level (i.e. 130 
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the same frequencies among levels of attributes) and a minimum overlap of levels for each 131 
attribute in each choice set. 132 
 133 
Data collection 134 
The survey included questions on socio-demographics, and aspects of health and vaccine 135 
experiences as identified from the literature. Trained research assistants screened the eligibility 136 
of participants identified in the paediatric specialist outpatient clinics in PMH and QMH 137 
between June 2014 and May 2015.  The purpose of the study was explained to all participants 138 
and written consent was obtained.  Each participant was presented with a choice to be surveyed 139 
in Traditional Chinese or English using an online platform (SurveyMonkey Inc, Palo Alto, 140 
California, USA, more information is available at www.surveymonkey.com ). The survey was 141 
conducted using a portable electronic device on either a laptop or tablet.  The research assistant 142 
accompanied each participant from commencement to completion of the survey with assistance 143 
on any queries they may have. Participants who refused to give consent were excluded from the 144 
study.  145 
 146 
Sample Size Calculation 147 
 148 
The experimental design consisted of eight choice set questions, each one examined by the 149 
respondents, and the largest number of levels for any of the attributes was four. According to 150 
Orme’s rule of thumb formula(25), at least 125 participants (500 x 4 ÷ 8 ÷ 2) are required for a 151 
two-alternative experimental design (the alternatives of two vaccines profiles and “no 152 
vaccination” did not have varying attributes).  153 
 154 
Statistical Analysis 155 
 156 
The DCE choices were analysed by a multinomial logistic regression model, which regressed 157 
the response to the choice question (i.e. vaccine 1, vaccine 2, or no vaccination) of the vaccine 158 
attributes and levels (see Table 1). For ‘no vaccination’ which is defined as the opt-out option, 159 
the levels of all attributes were all set to zero. It is assumed that there is a linearity in the levels 160 
of each attribute and there is no interaction between the attributes. By adopting the linear 161 
assumption, the marginal WTP would increase by the preference weight value with each 162 
percentage change of protection and side effects or each year change for protection duration. 163 
Therefore, the WTP could be determined by taking the ratio of the preference weight of the 164 
Running Title: WTP for HPV in Hong Kong 
6 
 
attribute to the preference weight of out-of-pocket cost. The marginal WTP, which represents 165 
the monetary value that the participant is willing to pay for per unit for the attribute, is calculated 166 
by multiplying the preference weight of the attribute with changes in levels per unit (i.e. % for 167 
protection against cervical cancer and side effects or year for protection duration) as shown in 168 
Equation 1. It can be derived from a specific case of the multinomial logistic regression model 169 
by solving the equation for this case for marginal WTP which is that the level for the attribute in 170 
question is set equal to one and the levels of all other attributes equal to zero. 171 
 172 
Equation 1:  
costpocket -of-out
attributeattribute
 WeightPreference
Level WeightPreference -  =  WTPMarginal ∆×  173 
 174 
To calculate the total WTP for a specific vaccine profile, the marginal WTP for each attribute 175 
could be added together as follows:  176 
 177 
Equation 2: 178 
 179 
 180 
The maximum WTP for development of the vaccine using ideal technology was calculated by 181 
incorporating 100% protection, lifetime protection duration (i.e. 100 years), and 0% side effects 182 
(i.e. Marginal WTP for 0% side effects = 0) into Equation 2. Furthermore, the total WTP for 183 
vaccines currently available is calculated by substituting the difference between the attribute 184 
levels of having the currently available vaccination (i.e. 70% protection against cervical cancer, 185 
10-year protection duration and 10% of side effects, which were generally obtained from related 186 
clinical literature (26-29)) and not having the vaccination at all (0% protection against cervical 187 
cancer, 0-year protection duration and 0% of side effects). The corresponding marginal WTPs 188 
were computed using equation 1 and adding them up by using equation 2. 189 
 190 
Nagelkerke's Pseudo R-square was reported to inform the goodness-of-fit of our regression 191 
models (30). The Nagelkerke's Pseudo R-square provides a measure of relative mode fit, ranging 192 
from 0 to 1 with higher values indicating better model fit. Regression model was considered as a 193 
good fit if Pseudo R-square ranged from 0.2 to 0.4(30). Regression coefficients estimates for 194 
each attribute with their corresponding 95% confidence intervals and the WTP were reported. 195 
Sub-group analyses were conducted for different groups of education levels (Primary 1 to 6 for 196 
those aged between 6-11 years old, junior secondary year 1 to 3 for those aged between 12-14 197 
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years old, senior secondary year 4 to 6 for those aged between 15-17 years old, tertiary leading 198 
to non-degrees and tertiary leading to degrees) and monthly household income (<HK$10,000; 199 
HK10,000-20,000; HK$20,001-30,000; HK$30,001-50,000; HK$50,001-100,000; and 200 
>HK$10,000). All statistical analyses were conducted using the Statistical Analysis System 201 
(SAS) version 9.3.  202 
 203 
Results 204 
 205 
Socio-demographic profiles and HPV perceptions 206 
 207 
A total of 482 mothers (equalling a response rate of 79.1%) were interviewed with 181 and 301 208 
complete responses from PMH and QMH respectively. The percentage of mothers who declined 209 
to participate the study was 20.9% with the main reasons for refusal given as not enough time or 210 
not interested in the study. Table 3 shows the respondents’ characteristics and experiences in 211 
relation to HPV or the HPV vaccine. The respondents had a mean age of 42.9 years, more than a 212 
half were born in Hong Kong and the majority were educated to secondary level or higher. Less 213 
than a half of the respondents had monthly household income more than HK$30,000. In general, 214 
respondents were familiar with the vaccine. More than three-quarters of the mothers had 215 
previously heard about the HPV vaccines and were concerned about their daughters’ risk of 216 
HPV infection and cervical cancer. However, more than a half of the mothers believed the 217 
vaccines are somewhat / very unsafe and some of them refused their daughter to be 218 
administered. More than 95% declared that either sex education or abstinence should be taught 219 
at school. 220 
 221 
Preferences and WTP for HPV vaccines of all respondents 222 
 223 
In the rationality test, 11% of mothers chose no vaccination whereas 88.4% of mothers made 224 
a more reasonable choice of higher protection effectiveness, longer protection duration and 225 
lower out-of-pocket costs and probability of side effects. 226 
 227 
With all the attributes treated as continuous variables in the regression, larger preference 228 
weights indicate a more-preferred vaccine attribute. For a specific attribute, a positive 229 
coefficient indicates that the corresponding attribute increases positivity and a higher level of 230 
this attribute is preferred. This also implies that a higher level of this attribute is associated 231 
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with a higher WTP as well as the increased likelihood to purchase. Conversely, a negative 232 
coefficient indicates that the attribute generates negativity and so lower levels are preferred. 233 
Table 4 shows the mothers’ preferences estimated from the statistical model. All the 234 
attributes have significant impact on WTP (p<0.001). Side-effects, protection against cervical 235 
cancer, protection duration, and out-of-pocket cost determined the decision to receive or not 236 
receive the vaccine. Our multinomial logistic regression had a pseudo R-square of 0.19612, 237 
indicating marginally acceptable model fit.  238 
 239 
The marginal WTP for each attribute and the overall WTP for the vaccine are reported in 240 
Table 5. For each attribute, zero was used as the reference group (i.e. no vaccination: 0% 241 
protection against cervical cancer, 0-year protection duration and 0% of side effects) for the 242 
corresponding marginal estimation of WTP. Vaccine effectiveness, defined as the cervical 243 
cancer protection rate, is highly valued with largest WTP margin of HK$5,431. Mothers are 244 
similarly willing to pay for lifetime protection (HK$3,545) and 0% side-effect (treated as 245 
HK$0). The maximum WTP for ideal vaccines developed (i.e. 100% protection, lifetime 246 
protection duration = 100 years and 0% side effects) is HK$8,976. It essentially reflects 247 
mothers’ perceived benefits and the great demand of eliminating their daughter’s risk of 248 
cervical cancer. On the other hand, the WTP calculated for vaccines currently available on 249 
the market is HK$1,620, which is relatively lower than the current market price (HK$4,500 250 
for full-course consisting of 3 injections). 251 
 252 
Preferences and WTP for HPV vaccines among different socio-economic groups 253 
 254 
To further explore the impact of socio-economic factors on mothers’ preferences and the WTP 255 
HPV vaccines, we conducted subgroup analyses on different levels of household income and 256 
education using the same statistical model. All the attributes showed a similar significant 257 
(p<0.05) impact on the WTP across all income and education groups, except the out-of-pocket 258 
cost attribute for primary education level. Preference weights and ranking of attributes were 259 
consistent with the overall analysis. 260 
 261 
Mothers’ WTP for current HPV vaccines among different education levels and income groups 262 
are accordingly illustrated in Figure 1. In general, the maximum WTP and WTP for current 263 
Running Title: WTP for HPV in Hong Kong 
9 
 
vaccines are positively correlated with education level. However, the maximum WTP for the full 264 
vaccine course peaked at non-degree tertiary level to the amount of HK$10,786 while the WTP 265 
for vaccines currently offered peaked at degree tertiary level to the amount of HK$1,942. It was 266 
also noted at a primary education level, the value of the WTP for current vaccines was negative 267 
(-HK$462) due to the greater negative impact of the marginal WTP of side effects than the 268 
positive impact of that of protection against cervical cancer and protection duration (see 269 
Appendix 2). 270 
 271 
Interestingly, in the stratified analysis for different income groups, both the maximum WTP and 272 
WTP for vaccines currently offered were higher for those with a household income level greater 273 
than HK$50,000 (see Figure 1). The income group with a monthly household income of 274 
HK$30,001-50,000 is willing to pay the least for both the ideal or currently-offered vaccine for 275 
the prevention of cervical cancer. Mothers with a monthly household income of >HK$100,000 276 
are the only one subgroup of the population who are willing to pay (HK$5,885) more than the 277 
current market price ($4,500) for vaccines currently offered. 278 
 279 
Discussion 280 
 281 
Cervical cancer is one of the common causes of cancer death and yet preventable cancers(1). 282 
The disease burden in Hong Kong is relatively higher than that in other developed countries (1). 283 
Currently, there is no universal organized vaccination program in Hong Kong while the HPV 284 
vaccination among teenage girls is largely opportunistic and the reported administration rate is 285 
continuously low (4, 8). Understanding the factors that determine the administration of the HPV 286 
vaccine is crucial for designing a more-effective vaccine-promotion program and for re-287 
evaluating current immunisation policies. It is particularly important in the light of the recently-288 
available and newly-developed 9-valent vaccine(31). As far as we are aware, this is the first 289 
local study using a quantitative approach and systemic analysis to reveal consumers’ preferences 290 
and the WTP in relation to HPV vaccines in Hong Kong. Our study suggests that the 291 
effectiveness of cervical cancer protection, the protection duration, side effects and out-of-292 
pocket costs are all significant factors in the determination of whether to administer the HPV 293 
vaccine. However, preferences and WTP for HPV vaccine are culture-specific and subject to 294 
socio-economic status as indicated by education level and household income. 295 
 296 
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In line with the previous studies(16-19), findings from this DCE survey demonstrate that 297 
'protection effectiveness' and 'protection duration' were significant attributes when making the 298 
decision of whether to administer the HPV vaccination. This may be attributed to the differences 299 
in culture, ethnicity and education levels in medical decision-making(32). For example, our 300 
sample group from Hong Kong appears to be more conservative on sexual health issues (such as 301 
believing abstinence should be taught in schools, a rate of 96.7% vs. 21.6%) and less educated 302 
(tertiary level education or above, a rate of 27.5% vs. 39.7%) when compared with mothers in 303 
the US(16).  304 
 305 
According to our survey, 80% of mothers have previously heard of the HPV vaccines, and the 306 
demand and conceived health benefits/risks from HPV vaccines are high as indicated by the 307 
maximum WTP. In the main and sub-group analyses, mothers’ maximum WTP was consistently 308 
beyond the market price for the currently-available vaccine, regardless of their education and 309 
income levels. The value of the HPV vaccination might reflect the fear of cervical cancer, in part 310 
contributed by health education and marketing for HPV vaccinations and cervical cancer 311 
prevention from diverse sectors in the recent years(33). On the other hand, the overall WTP for 312 
vaccines currently offered is still lower than the market price (HK$4,500) except for those with 313 
monthly household income of >HK$100,000 (HK$5,885). Subsidised or part-payment from the 314 
government should be considered for to help meet the demand for the HPV vaccination, similar 315 
to that of the Childhood Influenza Vaccination Subsidy Scheme(34) which encourages parents 316 
of children aged between 6 months and 6 years to let their children receive influenza 317 
vaccinations in private clinics. Nevertheless, the WTP for current vaccines (HK$1,620) is likely 318 
to be underestimated due to its 70% effectiveness against cervical cancer, 10-year protection 319 
duration and 10% of all side effects based on literature. With the launch of the 9-valent HPV 320 
vaccine and a longer follow-up period being offered, the WTP for vaccines is expected to 321 
increase, and subsequently, the effectiveness and protection duration will also increase. 322 
 323 
As expected, social disparity in Hong Kong is evident and the WTP of mothers varies depending 324 
on their monthly household incomes (P<0.001). However, it may be inappropriate to generalise 325 
the overall WTP to all consumers across Hong Kong when determining vaccination policy. As 326 
stratified by different income sub-groups (Figure 1), mothers with monthly household income of 327 
>HK$50,000 had a greater maximum WTP and WTP for vaccines currently being offered than 328 
mothers with an income of HK$50,000 or less. Mothers belonging to the monthly income group 329 
of HK$20,001-30,000 were willing to pay the least for either the vaccines currently offered or 330 
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those created by using ideal vaccines to prevent cervical cancer. However, mean WTP values of 331 
the sub-groups and the comparisons of WTP values between sub-groups should be interpreted 332 
with caution because there were no statistical inference tests for the mean differences in WTP 333 
values between sub-groups.  334 
 335 
Limitations 336 
 337 
Several limitations are worth mentioning. Firstly, although this is a stated-preference survey, it 338 
may also be argued that true preferences are not revealed as the decisions made are only 339 
hypothetical. However, we tried to maximize the validity of preferences by providing alternative 340 
options within the nine choice sets. Secondly, all choice sets considered a limited number of 341 
attributes based on the literature review and pilot study. Other attributes, especially for the 342 
protection against genital warts, may also reflect other preferences. Nevertheless, we included 343 
eight candidate attributes based on the best relevant literature available and selected the most 344 
important four attributes from the preferences of medical practitioners and mother at the pilot 345 
stage of the study. Our approach also reflects local stakeholders’ preferences and was efficient 346 
and practical for the DCE design and questionnaire (35). Thirdly, this study examined 347 
preferences among mothers who were seeking medical care for their children in paediatric 348 
specialist outpatient clinics in two public hospitals. This survey does not include preferences of 349 
the WTP for HPV vaccines among mothers who choose not to seek medical care for their 350 
children at that time or from among mothers take their children to private healthcare institutions. 351 
Thus, a selection and response bias from the convenience sampling method cannot be avoided 352 
and the general applicability of the findings of this study to Hong Kong as a whole must be 353 
cautiously interpreted. Fourthly, in the multinomial logistic regression, we treated all variables 354 
as continuous with a linear specification and no interaction between attributes. Respondents’ 355 
demographic characteristics and past experience of HPV/HPV vaccines were not adjusted in the 356 
model. Instead, we performed a stratified analysis based on income and the level of education 357 
that casts a light on the impact of social-economic factors of respondents’ preferences and their 358 
willingness to allow their daughters to receive the vaccine. Despite that, our multinomial logistic 359 
regression had a pseudo R-square of 0.19612, marginally attaining the lower bound of model 360 
good fit and thus supporting the linear continuous specification. Finally, despite the majority of 361 
factors related to the respondents’ socioeconomic status and knowledge of cervical cancer being 362 
collected (including household income, educational level, employment status, and past 363 
experience with cervical cancer/screening/vaccines), information on mothers’ insurance status 364 
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was not collected in this survey. From previous systematic review(36) and local surveys(37, 38), 365 
health insurance status was one of the most important socioeconomic factors that would impact 366 
their vaccination intention and decision. Further studies could collect information on the status 367 
of insurance which may be an important factor affecting the WTP of respondents. 368 
 369 
Conclusion 370 
 371 
Side-effects, protection against cervical cancer, protection duration, and out-of-pocket cost were 372 
significant attributes making the decision of whether mother with daughters of 8-17 years ago 373 
choice to vaccinate or not. This study provided data on how features of the HPV vaccine are 374 
viewed and valued by mothers by determining their perception of ideal or improved and current 375 
vaccine technologies. These findings could contribute to future policies on the improvement of 376 
HPV vaccine and be useful for the immunization service in Hong Kong. 377 
 378 
 379 
380 
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Figure Legend 467 
Figure 1. Willingness-to-pay for HPV vaccines by mothers’ education level (upper) and by 468 
monthly household income (lower). 469 
 470 
Figure 1. Willingness-to-pay for HPV vaccines by mothers’ education level (upper) and by 
monthly household income (lower) 
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Table 1. Vaccine profiles 
Profile 
Protection against  
cervical cancer 
Protection duration Side effects 
Out-of-pocket cost 
(HK$) 
Vaccine 1 80% 2 years 6 :100 3000 
Vaccine 2 50% Lifetime 10 :100 2000 
Vaccine 3 50% 5 years 14 :100 3000 
Vaccine 4 100% 2 years 10 :100 1000 
Vaccine 5 80% 5 years 10 :100 0 
Vaccine 6 100% Lifetime 2 :100 3000 
Vaccine 7 50% 2 years 2 :100 0 
Vaccine 8 80% Lifetime 14 :100 1000 
Vaccine 9 70% 10 years 10 :100 3000 
Vaccine 10 100% 5 years 6 :100 2000 
Vaccine 11 70% Lifetime 6 :100 0 
Vaccine 12 80% 10 years 2 :100 2000 
Vaccine 13 70% 5 years 2 :100 1000 
Vaccine 14 100% 10 years 14 :100 0 
Vaccine 15 50% 10 years 6 :100 1000 
Vaccine 16 70% 2 years 14 :100 2000 
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Table 2. Choice sets 
Choice set Vaccine profile (choose one only in each choice set) 
Rationality test Protection against cervical cancer 
= 50% 
Protection duration = 2 years 
Side effects = 10 : 100 
Out-of-pocket cost (HK$) = 3000 
Protection against cervical cancer 
= 80% 
Protection duration =Lifetime 
Side effects = 6 : 100 
Out-of-pocket cost (HK$) = 0 
No vaccination 
Choice set 1 of 8 Vaccine 1 Vaccine 2 No vaccination 
Choice set 2 of 8 Vaccine 3 Vaccine 4 No vaccination 
Choice set 3 of 8 Vaccine 5 Vaccine 6 No vaccination 
Choice set 4 of 8 Vaccine 7 Vaccine 8 No vaccination 
Choice set 5 of 8 Vaccine 9 Vaccine 10 No vaccination 
Choice set 6 of 8 Vaccine 11 Vaccine 12 No vaccination 
Choice set 7 of 8 Vaccine 13 Vaccine 14 No vaccination 
Choice set 8 of 8 Vaccine 15 Vaccine 16 No vaccination 
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Table 3. Characteristics of respondents 
Characteristics Total (N=482) PMH (N=181) QMH  (N=301) 
Socio-demographic, n (%) 
Mothers' age (Mean, standard deviation)  42.9 (5.5) 41.4 (5.6) 43.8 (5.2) 
Place of Birth       
 Hong Kong 282 (58.5%) 95 (52.5%) 187 (62.1%) 
 Mainland China 174 (36.1%) 72 (39.8%) 102 (33.9%) 
 Others 26 (5.4%) 14 (7.7%) 12 (4.0%) 
Education       
 Primary or below 27 (5.6%) 15 (8.3%) 12 (4.0%) 
 Secondary 322 (66.9%) 136 (75.1%) 186 (61.8%) 
 Tertiary or above 133 (27.5%) 30 (16.6%) 103 (34.3%) 
Monthly Household Income     
 <HK$10,000 33 (6.85%) 21 (12.5%) 12 (4.0%) 
 HK$10,000-20,000 130 (27.0%) 66 (36.5%) 64 (21.3%) 
 HK$20,001-30,000 84 (17.4%) 28 (15.5%) 56 (18.6%) 
 HK$30,001-50,000 103 (21.4%) 29 (16.2%) 74 (24.6%) 
 HK$50,001-100,000 89 (18.5%) 22 (12.2%) 67 (26.3%) 
 >HK$100,000 27 (5.6%) 4 (2.2%) 23 (7.6%) 
 No income-retired 6 (1.24%) 4 (2.2%) 2 (0.7%) 
 No income-unemployed 10 (2.8%) 7 (3.9%) 3 (1.0%) 
Number of Children (Mean, standard deviation) 1.84 (0.759) 1.94 (0.883) 1.78 (0.669) 
 1 161 (33.4%) 58 (32.0%) 103 (34.2%) 
 2 253 (52.5%) 87 (48.1%) 166 (55.2%) 
 >3 68 (14.1%) 36 (19.9%) 32 (10.6%) 
Personal history and attitudes toward HPV, cervical cancer and related tests, n (%) 
Has previously heard of HPV vaccines before completing this survey 385 (79.9%) 151 (83.4%) 234 (77.7%) 
Familiar with HPV 107 (22.2%) 42 (23.2%) 65 (21.6%) 
Familiar with cervical cancer 312 (64.7%) 113 (62.4%) 199 (66.1%) 
Knows a child/teenager who has had HPV vaccination 94 (19.5%) 28 (15.5%) 66 (21.9%) 
Personal history of HPV vaccination 23 (4.8%) 7 (3.9%) 16 (5.3%) 
Personal history of HPV infection 12 (2.5%) 5 (2.8%) 7 (2.3%) 
Personal history of cervical cancer 5 (1.0%) 2 (1.1%) 3 (1.0%) 
Personal history of other cancer 15 (3.1%) 4 (2.2%) 11 (3.7%) 
Personal history of abnormal Pap smear test result 26 (5.4%) 9 (5.0%) 17 (5.7%) 
Daughter has had Pap smear test 8 (1.7%) 1 (0.6%) 7 (2.3%) 
Has concerns about daughter's risk of HPV 363 (75.3%) 135 (74.6%) 228 (75.8%) 
Has concerns about daughter's risk of cervical cancer 370 (76.8%) 142 (78.5%) 228 (75.8%) 
Believes daughter not at risk of HPV because not sexually active 466 (96.7%) 175 (96.7%) 291 (96.7%) 
Refused vaccine for daughter 32 (6.6%) 7 (3.9%) 25 (8.3%) 
Believes vaccines are somewhat / very unsafe 267 (55.4%) 98 (54.0%) 169 (56.2%) 
Believes either sex education or abstinence should be taught at school 466 (96.7%) 174 (96.1%) 292 (97.0%) 
Note: HPV = human papillomavirus; PMH = Princess Margaret Hospital; QMH = Queen Mary Hospital   
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Table 4. Coefficients estimates for attribute main effects using multinomial logistic 
regression 
Attribute 
Preference 
Weights SE P-value 95% CI 
Protection against cervical cancer (%) 0.01633 0.0007514 <0.0001 (0.01486 0.0178) 
Protection duration (year) 0.01066 0.0005 <0.0001 (0.00968 0.01164) 
Side effects (%) -0.07626 0.00487 <0.0001 (-0.0858 -0.0667) 
Out-of-pocket cost (HK$) -0.0003007 0.0000207 <0.0001 (-0.0003 -0.0003) 
SE = standard error; CI = confidence level 
Notes:  
Nagelkerke Pseudo R2 = 0.19612 
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Table 5 Willingness-to-pay for the attributes of HPV vaccination 
Attributes Alternatives Marginal WTP (HK$) 
Protection against cervical cancer from 0% to 100% 5430.66 
from 0% to 80% 4344.53 
from 0% to 70% 3801.46 
from 0% to 50% 2715.33 
Protection duration 
  
from 0 years to lifetime 3545.06 
from 0 to 10 years 354.51 
from 0 to 5 years 177.25 
from 0 to 2 years 70.90 
Side effects 
  
  
  
from 0 to 14 in 100 -3550.52 
from 0 to 10 in 100 -2536.08 
from 0 to 6 in 100 -1521.65 
from 0 to 2 in 100 -507.22 
Maximum WTP*  8975.72 
WTP for current available vaccine**  1619.89 
WTP = Willingness-to-pay 
Notes: 
* Maximum WTP for ideal vaccines developed is calculated by incorporating 100% protection, lifetime protection duration (100 years) and 0% side 
effects (Marginal WTP for 0% side effects is treated as 0) 
** WTP for current vaccine calculated by incorporating 70% protection against cervical cancer, 10-year protection duration and 10% side effects 
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Appendices 
 
Appendix 1 List of Identified Attributes from Literature Review and Expert Interviews 
 
Attributes Levels Reference 
Protection against cervical cancer 50% / 70% / 90% de Bekker-Groba et al. 2010 
50% / 70% / 90% Poulos et al. 2011 
50% / 70% / 80% / 100% Brown et al. 2010 
90% / 95% / 98% / 100% Oteng et al. 2010 
Protection against genital warts No protection / 90% Brown et al. 2010 
No protection / 90% / 95% / 98% Oteng et al. 2010 
Need for vaccine booster Never / Every 5 years / Every 10 
years 
Oteng et al. 2010 
Target group to vaccinate Girls only / Girls and boys Oteng et al. 2010 
Protection duration 6 years / 25 years de Bekker-Groba et al. 2010 
2 years / 10 years / lifetime Poulos et al. 2011 
2 years / 5 years / 10 years / 
lifetime 
Brown et al. 2010 
Side effects  
- Serious  
- Mild side effects 
2:100 / 6:100 / 10:100 / 14:100 Oteng et al 2010 
1:750,000 / 1:150000 / 1:30000 de Bekker-Groba et al. 2010 
1:50 / 1:30 / 1:10 de Bekker-Groba et al. 2010 
Start age at vaccination 9 / 12 / 14 years old de Bekker-Groba et al. 2010 
Out-of-pocket cost 0 / 100 / 300 / 700 ($USD) Brown et al. 2010 
6 / 29 / 118 / 353 ($USD) Poulos et al. 2011 
0=insurance / 200 / 400 / 600 
($CAD) 
Oteng et al 2010 
 
  
2 
 
Appendix 2 Coefficients estimates for attribute main effects by mothers’ education levels 
 
Education level  Attribute Coefficient SE P-value 
Primary Protection against cervical cancer (%) 0.0073 0.00325 0.0244 
Protection duration (year) 0.01271 0.00219 <0.0001 
Side effects (%) -0.08228 0.02215 0.0002 
Out-of-pocket cost (HK$) -0.0003998 0.0000933 0.0819 
Junior Secondary Protection against cervical cancer (%) 0.01668 0.00176 <0.0001 
Protection duration (year) 0.01012 0.00116 <0.0001 
Side effects (%) -0.0733 0.01132 <0.0001 
Out-of-pocket cost (HK$) -0.0003104 0.0000482 <0.0001 
Senior Secondary Protection against cervical cancer (%) 0.01567 0.00107 <0.0001 
Protection duration (year) 0.01071 0.0007149 <0.0001 
Side effects (%) -0.06862 0.0069 <0.0001 
Out-of-pocket cost (HK$) -0.000284 0.0000293 <0.0001 
Tertiary (Non-
degree) 
Protection against cervical cancer (%) 0.0162 0.00249 <0.0001 
Protection duration (year) 0.00931 0.00168 <0.0001 
Side effects (%) -0.08897 0.0165 <0.0001 
Out-of-pocket cost (HK$) -0.0002365 0.0000689 0.0006 
Tertiary (Degree) Protection against cervical cancer (%) 0.02117 0.00183 <0.0001 
Protection duration (year) 0.01141 0.00118 <0.0001 
Side effects (%) -0.09315 0.01158 <0.0001 
Out-of-pocket cost (HK$) -0.0003422 0.0000505 <0.0001 
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Appendix 3 Coefficients estimates for attribute main effects by monthly household income 
 
Income level  Attribute Coefficient SE P-value 
<HK$10,000 
 
Protection against cervical cancer (%) 0.01663 0.00288 <0.0001 
Protection duration (year) 0.0084 0.00189 <0.0001 
Side effects (%) -0.07047 0.0186 0.0002 
Out-of-pocket cost (HK$) -0.0003836 0.0000787 <0.0001 
HK$10,000-20,000 
 
Protection against cervical cancer (%) 0.01443 0.00145 <0.0001 
Protection duration (year) 0.01089 0.0009646 <0.0001 
Side effects (%) -0.06716 0.00939 <0.0001 
Out-of-pocket cost (HK$) -0.00035 0.00004 <0.0001 
HK$20,001-30,000 
 
Protection against cervical cancer (%) 0.01609 0.0018 <0.0001 
Protection duration (year) 0.0113 0.0012 <0.0001 
Side effects (%) -0.07417 0.01164 <0.0001 
Out-of-pocket cost (HK$) -0.0002817 0.0000496 <0.0001 
HK$30,001-50,000 
 
Protection against cervical cancer (%) 0.01448 0.00164 <0.0001 
Protection duration (year) 0.01137 0.0011 <0.0001 
Side effects (%) -0.08713 0.01087 <0.0001 
Out-of-pocket cost (HK$) -0.0003579 0.0000464 <0.0001 
HK$50,001-100,000 
 
Protection against cervical cancer (%) 0.0211 0.00177 <0.0001 
Protection duration (year) 0.00967 0.00117 <0.0001 
Side effects (%) -0.08749 0.01129 <0.0001 
Out-of-pocket cost (HK$) -0.0001876 0.0000479 <0.0001 
>HK$100,000 Protection against cervical cancer (%) 0.03178 0.00385 <0.0001 
Protection duration (year) 0.01083 0.00224 <0.0001 
Side effects (%) -0.08357 0.02154 0.0001 
Out-of-pocket cost (HK$) -0.0002544 0.0000958 0.008 
 
 
